Home World News Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC,... World News Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population By Ogkologos - October 20, 2026 45 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZZ-FIRST study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 Changes to chromosomes impact how children’s brain tumours respond to treatment November 4, 2022 France Bans all Textured and Polyurethane Breast Implants Amid BIA-ALCL Cancer... April 5, 2019 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS Majority of Patients With Cancer Are Willing To Be Vaccinated Against... Investigating suspected prostate cancer: improving GP-patient communication Efficacy and Safety of Adding Antiangiogenesis Therapy to First-Line Immunochemotherapy in... That Cancer Conversation is back!
